SERACH RESULTS FOR" Development "
businessEthicBusiness Ethics BUSINESS PRINCIPLESSamsung's Management Philosophy is to "devote our human resources and technology to create superior products and services, thereby contributing to a better global society." Samsung's code of conduct is the foundation that allows us to create a fair, clean, and transparent corporate culture. BUSINESS ETHICS WEBSITE REPORTING WRONGFUL PRACTICES Samsung aims to be a 'world-leading company,' by devoting our human resources and technology to create best products and services, thereby contributing to a better society for all humans. To meet this goal, all Samsung employees share and pursue the Samsung Values of 「People, Excellence, Change, Integrity, Co-prosperity」. Furthermore, we have established and hereby declare to practice 「The Samsung Business Principles」 in a proactive manner in order to fully comply with all laws and ethical practices as well as to express our concrete commitment to our role and social responsibility as a corporate citizen. Laws And Ethics We comply with laws and ethical standards. 1-1 We respect dignity and diversity of individuals. The Company will respect the human rights of all employees.The Company will never allow forced labor, exploitation of wages and child slavery in any circumstances.The Company will not discriminate against stakeholders including customers and employees on the basis of national origin, race, gender, religion or any other characteristics protected by law. 1-2 We compete in accordance with laws and business ethics. The Company will accurately record and manage all transactions made so that all stakeholders can clearly understand our business activities.The Company will not obtain or gain illegally against business ethics.The Company will not permit the giving or acceptance of money, goods, entertainment or any economic benefits in doing business. 1-3 We maintain transparency of accounts with accurate recording of transactions. The Company will accurately record and manage all transactions made so that all stakeholders can clearly understand our business activities.The Company will comply with national and international accounting laws and regulations and internationally accepted accounting standards.The Company will disclose major business issues and corporate information such as change of financial status with due diligence in accordance with the law. 1-4 We do not get involved in politics and maintain neutrality. The Company will respect individual political rights and political opinions and at the same time not allow employees to perform any political activity within the organization.The Company's resources, including financial resources, manpower and facilities, shall not be used for political goals.The Company will refrain from illegal donations and any other giving of money for political reasons. Clean Organizational Culture We maintain a clean organizational culture. 2-1 We make a strict distinction between public and private affairs in our duties. When corporate interest comes into conflict with personal interest, the Company's legitimate interest shall come first.The Company shall not permit any illicit activity for the pursuit of personal gain, using one's position for private gain such as the embezzlement or misuse of corporate assets.Employees shall not conduct a transaction with marketable securities such as stock trading using the information acquired during the service of duties. 2-2 We protect and respect intellectual properties of the Company and others. Employees shall not leak corporate intellectual properties and confidential information without prior consent or approval to the outside.The Company will respect and not use, copy, distribute, or infringe on the intellectual properties of others in any other ways. 2-3 We create a sound organizational atmosphere. The Company has zero tolerance for any type of behavior that may hamper the relations between co-workers like sexual harassment, financial transactions and physical assaul
leadershipdevelopment through commercial supply stages. Furthermore, our experienced people provide expertise in cell line development, culture, purification, analytical testing, aseptic filling, and packaging. Our diverse capabilities, manufacturing scale, and flexibility represent a truly integrated one-stop service that meets all our clients’ needs. We will continue expanding our facilities and capabilities to meet growing market demand. As a global company, we pledge to continue Samsung’s legacy of excellence by combining our business, manufacturing, and engineering expertise, to bring innovation and progress to today’s biopharmaceutical industry. Sincerely yours, Dr. Tae Han KimPresident & CEO, Samsung BioLogics Key utives UTIVE VICE PRESIDENTKyusung Lee, Ph.D.Dr. Kyusung Lee is utive Vice President in charge of Contract Manufacturing Operation 1 of Samsung BioLogics. Prior to joining Samsung in 2010, Dr. Lee held various leadership positions in biopharmaceutical companies in the U.S. Dr. Lee began his career with Miller Brewing Company in 1991 as a biochemical engineer. He led the production team for Amoco BioProducts Corporation from 1992 to 1995 and was responsible for the technology transfer of a full scale biotechnology process, after which Dr. Lee moved to Merck & Co. During his tenure at Merck from 1995 to 2005, Dr. Lee participated in the design, construction, start-up, technology transfer, and commercial operation of biologics and pharmaceutical manufacturing facilities. From 2005 to 2010, Dr. Lee assumed responsibilities for technology transfer activities for Bristol-Myers Squibb Co.'s CMO programs. Dr. Lee holds a doctoral degree in chemical engineering from Purdue University. UTIVE VICE PRESIDENTJohn RimJohn Rim is utive Vice President in charge of Contract Manufacturing Operations 2 comprising the newest plant within Samsung BioLogics. Prior to joining Samsung BioLogics in 2015, Mr. Park held various technical and operational positions, as well as business development management leadership positions in biopharmaceutical companies in the U.S. Mr. Park began his career in 1989 with ALZA Corporation, a subsidiary of J & J, as a chemical engineer where he participated and led process and product development, technology transfer, validation and commercialization of several OROS products. He then worked in Technical & Alliance Management at Watson Pharmaceuticals. Transitioning to Merck as a Change Agent/Six Sigma Project Manager, Mr. Park then managed the Operational Excellence projects related to process improvements, cost savings and quality initiatives. From 2004 to 2015, Mr. Park participated in and directed 100+ CMC due diligences on assets ranging from pre-clinical to commercial products, and managed Global Manufacturing & Supply BD activities including Licensing, Outsourcing and M&A at Bristol-Myers Squibb. Mr. Park has over 25 years of experience in the biopharmaceutical and pharmaceutical industries. CFODongjoong KimDongjoong Kim is Senior Vice President and Managing Director in charge of the Business Resources Innovation Center which includes the Finance Team, Business Innovation Team, Corporate Information Technology Team, and Global Employee Satisfaction Team. Prior to joining Samsung BioLogics in 2014, Mr. Kim held various corporate planning and managerial leadership positions for Samsung Electronics. Mr. Kim began his career with Samsung in 1988. Mr. Kim led the Corporate Management and Administration of Samsung Electronics from 2002 to 2014. CBOJames ParkJames Park is Senior Vice President and Managing Director of the Global Business Development Center responsible for BD Operations Team, BD Innovation Team and Integration & Marketing Part of Samsung BioLogics. Prior to joining Samsung BioLogics in 2015, Mr. Park held various technical and operational positions, as well as business development management leadership positions in biopharmaceutical companies in the U.S. Mr. Park began his career in 1989 with
historyDevelopment Partnership with EutilexOCT. 2018 AEO CertificationOCT. 2018 Plant 3 cGMP ReadyJul. 2018 First DP Approval by FDAJul. 2018 Manufacturing Partnership with UCBJUN. 2018 Development Partnership with GI InnovationJUN. 2018 First Approval of Plant 1 by Health CanadaApl. 2018 ISO 22301 Certification (BCMS)DEC. 2017 First Approval of Plant 2 by EMANOV. 2017 Plant 3 Mechanical CompletionOCT. 2017 MOU for Strategic Alliance with MerckSEP. 2017 First Approval of Plant 2 by FDAJUL. 2017 Manufacturing Partnership with Sun PharmaMAY. 2017 First Approval of Plant 1 by PMDASamsung’s Innovative DesignPLANT 2 The Largest Single Plant5X Scale (DS 15,000L + DP Fill/Finish)Total Capacity - 152,000L (10x15,000L / 2x1,000L)Construction - 29 months to cGMP ready2016NOV. 2016 Samsung BioLogics IPO on KOSPINOV. 2016 First Approval of Plant 1 by EMAFED. 2016 Plant 2 DS cGMP ReadyNOV. 2015 First Approval of Plant 1 by FDANOV. 2015 Plant 3 Construction StartedOCT. 2015 Plant 1 PLI ApprovalFEB. 2015 Plant 2 mechanical CompletionAPR. 2014 Manufacturing Partnership with BMS2011-2013Standard DesignPLANT 1 Industry StandardIndustry Average Scale (DS 30,000L + DP Fill/Finish)Total Capacity - 30,000L (6x5,000L)Construction - 25 months to cGMP ready2013OCT. 2013 Manufacturing Partnership with RocheSEP. 2013 Plant 2 Construction StartedAug. 2013 Plant 1 DP cGMP ReadyJul. 2013 Manufacturing Partnership with BMS JUN. 2013 Plant 1 DS cGMP ReadyJUL. 2012 Plant 1 Mechanical CompletionMAY. 2011 Plant 1 Construction StartedAPR. 2011 Foundation of Samsung BioLogics
Drug ProductDevelopmentSamsung BioLogics provides Formulation services for Drug Product Fill and Finish. Formulations can be completed from both single use systems or hard pipe systems. Additionally, we provide optimized type formulations while securing stability and effectiveness for the customer within the time they need. We are also fulfilling customer satisfaction through development service that considers even the permitted articles following the relevant formulations. Core EquipmentSmall scale lyoDown Flow BoothDSCKarl FisherFreeze Dryer MicroscopeManual Filler (Peristaltic Type)Specialized CapabilityBiopharmaceuticalsMonoclonal antibodiesFusion proteinsBispecific antibodiesPackaging (Vials)ProteinsPeptidesFormulation process optimization based on QbDFormulation DevelopmentFormulation DevelopmentThawEquipmentFreeze/Thaw skid for cryovesselsFreeze/Thaw skid for cryobagsCapacity/CapabilityControlled freezing and thawingMax. capacity : 1 tank per stationTemperature range : -70ºC to 40ºCThawThawFormulationPlant 1EquipmentExcipient and formulation vesselsCapacity/CapabilityExcipient vessel capacity : 20L to 3,000LFormulation vessel capacity : 20L to 1,500LpH and temperature controlWeight controlCIP/SIP of excipient and formulation vesselsSingle use solutions capabilitiesPlant 2EquipmentExcipient and formulation vesselsCapacity/CapabilityExcipient vessel capacity : 200L to 2,000LFormulation vessel capacity : 200L to 2,500LpH and temperature controlWeight controlCIP/SIP of excipient and formulation vesselsSingle use solutions capabilitiesVial Preparation and FillingPlant 1EquipmentWashing, depyrogenation, vial fillingStoppering, capping, transfer to lyoCapacity/CapabilityActive RABSFilling rate : up to 12,000 vials/hrFilling operation range : 0.1 ~ 100mlPump types : piston and peristalticCIP/SIP of vial filling machine2mL to 50mL vial sizeGRADE A over sealingAdaptable process to include single use or fixed systemsInline IPC capability (non-destructive testing)Plant 2EquipmentWashing, depyrogenation, vial fillingStoppering, cappingCapacity/CapabilityActive RABS, Piston & Peristatic PumpMax. capacity : 300 vials/min (based on 10ml vial)Filling operation range : 0.1ml to 100ml100% weight check systemCIP/SIP of vial filling machineGRADE A over sealing (enclosed RABS)Adaptable process to include single use or fixed systemsVial Preparation and FillingVial Preparation and FillingInspectionManual InspectionEquipmentManual inspection BoothsCapacity/CapabilityComprehensive visual inspection programOperators' manual inspection qualificationProduct type : liquid, high viscosity, and lyophilizedDefect classification library and qualification programs developed for all product typesVial cap printing capabilities availableSemi Automatic and Automated InspectionEquipmentAutomated inspection lineCapacity/CapabilityLine speed : 12,000 vials/hr (20R vial)Uses Charge Coupled Device (CCD) camera system to identify vial defects, product defects, closure defects, etc.InspectionInspectionPackagingEquipmentManual bulk packagingCapacity/CapabilityLine speed : 18,000 vials/hr (30mm diameter vial)Pakaging type : labeler, cartoner, overwrapperLaser carton print systemAutomatic weight check unit between cartoner and overwrapperPackagingLYOPHILIZATIONEquipmentTwo(2) lyophilizersCapacity/CapabilityMax. loading capacity : 32,000 vials (10ml) per lyoIce load capacity : 300kgShelf area : 16.7 ㎡Automatic loading and unloading system with RABSLyophilizationLyophilizationLyophilization Cycle Development and Commercial ScalabilityLyophilized product design Product characterization Thermal characterization of product (Tg, Tg’, Teu,Tc)Characterization of freezing step (crystalline or amorphous)Finished product analysis specific to lyophilized products Karl Fisher moisturePhysical appearanceAttributes of constituted solution (time, clarity, PM)Lyophilized formulation development support Manufacturing of small-scale batches for development stability Troubleshooting commercial
Drug SubstanceDevelopment StagecGMP clinical & commercial cGMP clinical & commercial Plant SpecificationsShaker or Magnetic Stirring Flask CultureHybrid Depth Filtration System (POD, Typical Lenticular)Cultivation Type: Fed-BatchCentrifuge Shaker or Magnetic Stirring Flask CultureHybrid Depth Filtration System (POD, Typical Lenticular)Cultivation Type: Fed-Batch, Perfusion GMP OperationalQ3 2017 Q2 2020 (planned) Regulatory ComplianceGlobal HA including FDA, EMA, PMDA, MFDS, Health Canada Purification Specifications items include CMO 1 CMO 1 TypeDS 1 DS 2 Total Capacity30,000L 150,000L Production Scale5,000L (x 6)Three Trains 15,000L (x 10)Five Trains Bioreactor TypeStainless Steel Stainless Steel Development StagecGMP late clinical & commercial cGMP late clinical & commercial Plant SpecificationsShaker or Magnetic Stirring Flask CultureHybrid Depth Filtration System (POD, Typical Lenticular)Cultivation Type: Fed-BatchCentrifuge Shaker or Magnetic Stirring Flask CultureLenticular Depth Filtration SystemCultivation Type: Fed-BatchCentrifuge GMP OperationalQ3 2013 Q1 2016 Regulatory ComplianceGlobal HA including FDA, EMA, PMDA, MFDS, Health Canada Purification Specifications items include CMO 2 CMO 2 TypeDS 3 Total Capacity180,000L Production Scale15,000L (x 12)Six TrainsTwo DSP Trains Bioreactor TypeStainless Steel Development StagecGMP late clinical & commercial Plant SpecificationsShaker or Magnetic Stirring Flask CultureLenticular Depth Filtration SystemCultivation Type: Fed-Batch, PerfusionCentrifuge GMP OperationalQ4 2018 RegulatoryComplianceGlobal HA including FDA, EMA, PMDA, MFDS, Health Canada Equipment/Capability Equipment/CapabilityStart TourEquipment/CapabilityEquipment/Capability Equipment/CapabilityEquipment/CapabilityEquipment/CapabilityEquipment/Capability pause PurificationMaximum Flexibility & Minimum Turnover TimeSamsung BioLogics’ cGMP Drug Substance Downstream Purification consists of two facilities with the newest equipment for cGMP operations, including chromatography (e.g., affinity, ion-exchange, multi-modal), viral filtration, ultrafiltration/diafiltration (UF/DF), and formulation and bulk filling operations. Both facilities consist of physically segregated pre-viral and post-viral suites designed for maximum flexibility and minimum turnover time.Industry Leading Automation SolutionsEach downstream facility can be adjusted to accommodate all customer process needs. All purification facilities are classified as Grade C or higher. The design minimizes opportunities for cross-contamination with physically segregated pre-viral and post-viral suites containing equipment dedicated to cleaning areas and a Grade B bulk fill room. Three separate column packing suites support optimization of production cadence. The high-capacity buffer preparation suites are designed for temperature control and contain hold tank sizes to handle buffer preparations up to 15,000 L. The downstream suites are equipped with chromatography skids, columns, UF/DF skids, virus filtration skids, and Grade A (laminar flow booth) bulk filling capacity as well as product pool vessel capacities from 200 L to 15,000 L to handle a wide range of pool volumes and high protein titers. Our purification process is supported by industry leading automation solutions.SpecificationFacility design based on gravity flowPlant dedicated utility committed to providing constant power supplyChromatography : Affinity, Ion Exchange, Hydrophobic, Multi-modal Columns range : 0.8m to 1.8m in diameter Automation controls integrated with MCS Columns to accommodate all range of sizesDedicated equipment for Pre-Viral and Post-Viral areas for cross-contamination control COP and glassware parts washers Autoclaves Utility station with CIP and SIP capabilities for portable equipment CIP and SIP capabilities for all production equipmentVF Operation : Fully automated Hybrid design to accommodate any configurationUFDF Operation : Fully automatedIn line and off line Recirc vessel ca
ResearchDEVELOPMENT Effective ProcessSamsung BioLogics develops both liquid and lyophilized drug products. We have an efficient platform process of formulation development based on Design of Experiment (DoE) approach, followed by stability test in long-term, accelerated and stressed conditions. This systematic platform process can help to save development time to IND. Formulation Development Liquid Formulation- Basic buffer & Excipient screening- DoE based Pre-formulation optimization- Nominal / Accelerated pre-stability test- Product impactassessment Lyophilization Development- Characterization of the freezing step- Lyophilized formulation development- Lyophilization cycle optimization- Manufacture of small scale batches Non-GMP Manual Filling- Aseptic manual filling for pre-clinical study- 2R-20R with flip-off al-cap crimping- Watson Marlow PF7 filling machine Other Activities1. Lyophilization Development- Characterization of the freezing step- Lyophilized formulation development- Lyophilization cycle optimization- Manufacture of small scale batches2. Non-GMP Manual Filling- Aseptic manual filling for pre-clinical study· 2R~20R with flip-off al-cap crimping· Watson marlow PF7 filling machine Equipment Capacity / De ionBio-safety Cabinet Formulation and other experiments preparationIncubator Stability storage during formulation screening (25C and 40C)Spectrophotometer Protein / DNA concentration analysisCentrifuge General analysisMicro-centrifuge General analysisDSC (MicroCal) Formulation stability simulationDLS (ZetaSizer) Confirm particle size distributionMFI Confirmation of aggregation in DS & DPLiquid Particle Counter (HIAC) Sub-visible particle measurementHPLC Target molecule identification (SEC, CEX, AEX) CRO SERVICESWe provide full CRO service including Contract QC (Release & Stability Testings) to support our client’s successful product launch in Korea BTS : Bio-safety Testing Service Mycoplasma Detection Testing- EP and USP Mycoplasma Culture Method Detection- JP Mycoplasma Culture Method Detection- EP Mycoplasma DNA Detection by PCR* Types of Mycoplasma : Mycoplasma hyorhinis, M. orale, M. fernentans, M.pnuemoniae, M. gallisepticum, Acholeplasma laidlawii Adventitious Virus Testing- In Vitro Assay for MRC-5, Vero and CHO-K1- In Vitro Co-culture / PG S+L- Focus Assay- Specific Virus DNA Limit Detection by qPCR* Types of Virus : Measeles virus, Parainfluenza virus 3, Parainfluenza virus 5, Munute virus of mice (MVM) Microbial Testing- Sterility Testing- Endotoxin Detection / LAL Test- Bioburden- Microbial identification Contract QC Service General Characteristics- Apperarance- Osmolality- pH- Sub-visible particles Chemical- A280- Peptide mapping- HPLC- N-glycan profiling Biological- Cell-based potency- ADCC- Antibody Proliferation Assay Biochemical- SDS-PAGE- iCIEF- DNA qPCR- CE- HCP ELISA
development data to mass production technology, which are highly business sensitive and critical information for the client. “This achievement is exemplary of our dedication and continuous drive to further enhance the client experience, trust, and satisfaction at Samsung Biologics,” said Andy Kim, VP, in charge of Information Security. Winning the CMO Leadership Awards for six consecutive years since 2013, Samsung Biologics has proven its expertise and reliability with a continued strength in high-quality product manufacturing and cost-effective services. With its ability to address clients’ needs all from a single site, Samsung Biologics is a qualified CDMO as repeatedly chosen by clients and is uniquely able to support the development and manufacturing of both large and small scale at every stage of the process while meeting the evolving needs of biopharma/pharma companies worldwide.
development as a potential treatment for moderate-to-severe atopic dermatitis.Additionally, the product has a mechanism of action that enables the treatment of ‘a range of autoimmune diseases’, including atopic dermatitis, the companies stated.The agreement comes as Ichnos has completed enrollment in a Phase IIb clinical study for ISB 830, with results expected during the first half of 2020, and prepares to advance the candidate into Phase III clinical trials.A spin-out company of Glenmark, Ichnos was launched earlier this month with a portfolio of five clinical stage assets across the oncology, autoimmune disease, and pain therapeutics areas. Samsung had signed an agreement to provide process development and manufacturing services for ISB 830 with Glenmark in 2017. According to the companies, the prevalence of atopic dermatitis in seven major markets (US, France, Germany, Italy, Spain, the UK, and Japan) currently exceeds 80 million patients, with the market expected to grow to $18.3bn (€16.53bn) by 2027.
development as a potential treatment for moderate-to-severe atopic dermatitis. Based on an entirely new mechanism of action, ISB 830 has the potential to treat a range of autoimmune diseases beyond atopic dermatitis. Enrollment in a large randomized placebo-controlled Phase 2b study in atopic dermatitis was recently completed and results are expected in the first half of 2020. The prevalence of atopic dermatitis in the seven major markets (U.S., France, Germany, Italy, Spain, the UK, and Japan) currently exceeds 80 million patients and the market is expected to grow to $18.3 billion by 2027, according to GlobalData, a leading data and analytics company. Ichnos, headquartered in Paramus, NJ, is a fully integrated global biotech company that is rapidly advancing its pipeline and has five novel, first-in-class candidates in clinical stage development. Samsung Biologics and Ichnos (formerly known as Glenmark Pharmaceuticals S.A.) entered into a Master Services Agreement in 2017 for Samsung Biologics to provide Ichnos with process optimization and manufacturing services. Ichnos and Samsung Biologics have now entered into a long term agreement for Samsung Biologics to manufacture drug substance for ISB 830 Phase 3 clinical trials and for potential future global commercial supply upon regulatory approval. “As we progress our pipeline of clinical stage assets, including our most advanced biologic ISB 830, we are pleased to continue to work with Samsung Biologics to ensure continued drug substance supply for ISB 830,” said Alessandro Riva, chief utive officer, Ichnos Sciences. “We look forward to a mutually beneficial collaboration as we continue developing ISB 830 for autoimmune diseases, including atopic dermatitis.” Since the beginning of the relationship, Samsung Biologics has continued to offer flexible business terms and the latest standards in technologies, along with maintaining the highest quality with full regulatory support and improved batch release from small to large scale. This long-term relationship aims to bring further growth to both companies with the goal of bringing ISB 830 to market for the treatment of atopic dermatitis and other autoimmune diseases. “We are extremely proud to advance our ongoing relationship with Ichnos and truly appreciate the trust they have placed in Samsung Biologics to ensure delivery of high quality ISB 830 drug supply for clinical studies and for potential future commercial supply,” said Tae Han Kim, chief utive officer, Samsung Biologics. “Client satisfaction is our highest priority, and we look forward to generating future value for Ichnos via our continued collaboration.”Visit Samsung at CPhI Worldwide booth 120D02.
DevelopmentBusiness DevelopmentBD PlanningCorporate Business OperationPlanningProcurementLegal & CompliancePRCorporate managementFinanceInformation TechnologyHuman resources Application MethodComplete and submit application form to the e-mail address for recruitment at Samsung BioLogics. E-mail email@example.comPassing of the application procedures and employment may be cancelled if the contents of the application form are found to be false. ※ Download Application Form REGISTER IN TALENT POOL Registered applications of candidates in talent pool are primarily reviewed for positions on demand.
DevelopmentBusiness DevelopmentBD PlanningCorporate Business OperationPlanningProcurementLegal & CompliancePRCorporate managementFinanceInformation TechnologyHuman resources Application MethodComplete and submit application form to the e-mail address for recruitment at Samsung BioLogics. E-mail firstname.lastname@example.orgPassing of the application procedures and employment may be cancelled if the contents of the application form are found to be false. REGISTER IN TALENT POOL Registered applications of candidates in talent pool are primarily reviewed for positions on demand.
DEVELOPMENTSystematic training opportunities for the development of our employees’ values and competencies Values Develop Professional Competency to Lead the Bio-IndustryTo train the core values and unique culture of our company, we provide a range of educational courses for our employees. As a leading expert in the bio-industry, our employees can foster their ability for collaboration with collective intelligence and pride. Leadership Development of Leadership Capabilities for Mutual GrowthWe provide our employees with the opportunities to develop various leadership skills and abilities. Through these opportunities which include leadership training courses based on different levels and optimized courses for the role as a leader, effective communication skills and coaching abilities will be continually developed. Global Understanding Different Cultures and the Improvement of Communication SkillsWe provide an education program which broadens the understanding of different cultures through the development of communication skills that are an essential component. In-company language courses (including Korean courses for global employees) and Biz. Skill Up online courses support each employee as they seek to strengthen their ability to ute successful global businesses. Expertise A Compulsive Training Program for Professionalism DevelopmentWe provide a training program for our employees to improve expertise in OA, financial costs, and GMP that are vital requirements in the biopharmaceutical industry. In addition to that, in-company Biotech is supported for the purpose of training and the acquirement of technical knowledge.
Samsung BioLogics (hereinafter, the “Company”) values users’ personal information, complies with statutory obligation s on protection of personal information such as the Act on Promotion of Information and Communication Network Utilization and Information Protection, etc. and the Act on Protection of Personal Information, and has created a Policy to Handle (Process) Personal Information to protect the users’ right and interest to the maximum extent possible.
Through the Policy to Handle (Process) Personal Information, the Company publicizes its operations on personal information treatment (processing) with particulars such as the types of personal information collected from the users and the purpose of processing such information, the time limit for processing and holding in possession, users’ method to exercise their rights, measures to procure the security, and so on.
Whenever there is a change in the Policy to Handle (Process) Personal Information, including updating, deleting, or adding its contents, whether resulting from any amendment to the relevant statutory sources or the administrative policy or change in the Company’s internal policy, we will post the change on our website at www.samsungbiologics. com so as to keep the users updated.
The Company’s Policy to Handle (Proce ss) Personal Information contains the following:
The Company collects personal information for the following purposes. The pfi will not be used for any other purpose and whenever it is necessary to change the purpose, we will comply with the statutory requirements such as obtaining users’ consents in advance.
Review and reply to the inquiries from users
Check employment history, give notices for future recruitment opportunities.
|Required||Name, Email Address, Company, Occupation, Country, Areas of Interest|
|Optional||Job Title, Phone Number|
The following information may be generated and collected in the course of using the service.
Access long, cookie
Collection through Contact Us, Talent Pool within the Website
Collection through generated information collection tool (for access long, cookie, etc.)
Personal information that needs to be collected and utilized inevitably as specifically required by law or regulations, or in order to comply with statutory requirements : As long as it is necessary to keep such information in possession under relevant statute.
Personal information that needs to be collected and utilized inevitably in order to execute and perform various contracts: Until the purpose of collection/utilization is accomplished.
Personal information collected and used with the consent of individual user: For the time period consented to.
If the user has given his/her consent in advance.
If it is specifically required by laws or regulations or inevitable in order to comply with statutory requirements, or if it is deemed necessary for the sake of life, body or property of the information owner or a third party when the information owner or his/her legal representative is under a state incapable of communication or unable to give consent due to unknown domiciles or otherwise (only to the extent the purpose of collecting personal information is served).
User’s personal information
History of the users personal information being utilized or provided to a third party
History of consents given to collection, utilization and provision of personal information
If it is specifically required by laws or regulations or inevitable in order to comply with statutory requirements.
If it is likely to jeopardize a person’s life or body or unjustly infringe a person’s property or other interests.
The Company is operating cookies that regularly stores and locates users’ information.
How to install cookies (if using Internet explorer 8.0) Select “Internet Option” in the “Tool”. Click “Privacy” tab. Using “Setting”, users may set the level of allowing cookies as suitable for their own needs.
How to view the cookie received (if using Internet explorer 8.0)
Select “Internet Option” in the “Tool”. Click “General” tab and select “Setting” of the Browsing History to check the files in “View Files”.
How to disallow cookie installation (if using Internet explorer 8.0) Select “Internet Option” in the “Tool”. Click “Privacy” tab. Using “Setting”, set it to the higher level, that is, “Block All Cookies”
in handling users’personal information, the Company endeavors to keep the personal information from being lost, stolen, revealed, tampered or damaged. To this end, the following technical and managerial actions are taken.
The Company implements its own internal management plan to secure safety in processing the personal information.
The Company is operating an internal organization dedicated to personal information protection to monitor the status of compliance with the personal information protective requirements and the responsible staff’s duty performance and takes corrective measures when any irregularity is found.
Installation and operation of access restriction device Using the intrusion blocking system, the Company controls any unauthorized access from outside and endeavors to procure all the technological system to the maximum extent feasible in order to secure systematic security.
Minimized designation of personal information processors and education The Company minimizes designation of personal information processors and implements internal and/or outsourced education on a regular basis. Personal information processors’ duty handover is conducted with the security fully maintained and their responsibilities for any personal information accident are clearly defined even after they have left the Company.
Restrictions on access to personal information The Company places restrictions on access to personal information through granting, changing or revoking the right to access to database system that processes personal information. We also record the history of granting, changing or revoking the right, which are retained for our records for at least three years.
The personal information of users is protected by the password and the file and transmission data are encrypted or stored by using file lock function. More important data are protected through certain separate security measures.
The Company has adopted security devices that enable safe transmission of personal information on the network using encryption algorithm.
To safeguard personal information from leak or loss by hackers or computer viruses, the Company has installed a security program and conducts periodic updating and reviewing.
For unmistakable security operation, every server is installed with intrusion blocking system as a means to block outsider intrusion by hacking as well as a system to analyze vulnerability.
To protect users’personal information and handle personal information-related customer complaint, the Company has appointed a personal information manager and processor. Any inquiry related to personal information protection and management should be directed to the personal information processor for instant and adequate reply.
Division: General Affairs Security Part, Personnel Management Team
Any user seeking to relief from personal information infringement may apply for resolution or consultation to Personal Information Dispute Mediation Committee, Korea Internet and Security Agency (Personal Information Grievance Center). In addition, users may contact the following institutions to be consulted on personal information infringement cases.
Personal Information Dispute Mediation Committee (118)
Korea Internet and Security Agency (Personal Information Grievance Center)(www.kopico.or.kr/1336)
Information Protection Mark Verification Committee (http://eprivacy.or.kr/02-580-0533~4)
Internet Crime Investigation Center of the Supreme Prosecutors’ Office
Cyber Police Agency (www.police.go.kr/1566-0112)
Personal information Protection Committee (http://privacy.kisa.or.kr/kor/main.jsp)/02-2180-3000)
When this ‘Policy to Handle (Process) Personal Information’ needs to be changed to reflect the change in statutory sources or government policies, we will put such change in public notice through an advisory statement and a separate window on the website.
Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.